AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Alector to Present at Three Healthcare Conferences in September 2025
ByAinvest
Friday, Aug 29, 2025 7:58 pm ET1min read
Alector, a late-stage clinical biotech company, will present at three healthcare investor conferences in September 2025. The company's presentations will be available via webcast on its investor relations website, with replays accessible for up to 90 days. Alector is focused on developing therapies for neurodegeneration, including frontotemporal dementia, Alzheimer's disease, and Parkinson's disease, using its proprietary Alector Brain Carrier platform.
Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company specializing in neurodegenerative disease therapies, has announced its participation in three upcoming healthcare investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference 2025, Morgan Stanley 23rd Annual Global Healthcare Conference, and H.C. Wainwright 27th Annual Global Investment Conference, all taking place in New York City.Alector's management will engage in fireside chats and company presentations at these events, with webcasts available for attendees and investors. The webcasts will be accessible on Alector's investor relations website for 90 days following each conference [1].
The company focuses on developing therapies to counteract the progression of neurodegenerative diseases such as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. Alector's proprietary Alector Brain Carrier (ABC) platform aims to enhance the delivery of therapeutics, achieve deeper brain penetration, and improve patient outcomes [1].
Alector's involvement in these conferences comes amidst positive developments in the biotech sector. Coya Therapeutics (NASDAQ: COYA), another biotech company focused on neurodegenerative diseases, has recently received a Buy rating from BTIG, with a $15.00 price target, citing positive clinical data for its COYA-302 therapy in ALS and FTD patients [2].
References:
[1] https://www.globenewswire.com/news-release/2025/08/28/3140717/0/en/Alector-to-Participate-in-Upcoming-Healthcare-Conferences.html
[2] https://www.investing.com/news/analyst-ratings/coya-therapeutics-stock-maintains-buy-rating-at-btig-on-positive-als-data-93CH-4208464
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet